Final Presentation Slide - Incepta

GROUP DETAILS Name

ID

Roll

MD. Abu Bakr Siddique

1 31 0 75 8 030

13

Akib Ahmed

1 22 0 36 0 630

04

SK. Shamsad Hossain

1 32 0 29 2 030

20

Akash Alam

1320291630

19

Iftekharul Alam

1 41 0 41 0 630

36

Mahtab Hossain Khan

1 32 1 13 5 630

24

Ridwan Abir

1 32 1 13 6 630

25

Md. Adeel Anjum

1 32 1 31 1 630

27

COMPANY BACKGROUND

HISTORY •

INCEPTA PHARMACEUTICALS LTD. IS A LEADING PHARMACEUTICAL COMPANY IN BANGLADESH

•

ESTABLISHED IN THE YEAR 1999

•

BIG MANUFACTURING FACILITY LOCATED AT SAVAR

•

THE COMPANY SPECIALIZES IN VALUE ADDED HIGH TECHNOLOGY DOSAGE

•

AFTER BEING SUCCESSFUL LOCALLY THEY ARE OPERATION GLOBALLY

•

ACCREDITED WITH THE UK MHRA GMP CERTIFICATE

•

SINCE JULY 2011 THEY ARE MARKETING PRODUCTS IN UK

MISSION & VISION •

MISSION- PROVIDE QUALITY HEALTHCARE PRODUCTS AND SERVICES FOR THE BENEFIT OF HUMANITY IN THE BEST POSSIBLE WAY THROUGH INNOVATION AND DIVERSIFICATION.

•

VISION- OUR VISION IS TO BECOME A TRUSTED HEALTHCARE COMPANY TO ENSURE BETTER HEALTH FOR EVERYONE, EVERYWHERE

VALUE CHAIN ANALYSIS •

INCEPTA HAS A LARGE DISTRIBUTION NETWORK.

•

PRODUCTS AVAILABLE IN EVERY SINGLE DRUG STORE.

•

PRODUCTS ALSO SUPPLIED TO REMOTE AREAS.

•

THERE IS A LARGE FLEET OF TRANSPORT INCLUDING REFRIGERATOR TRUCKS FOR SUPPLYING TEMPERATURE SENSITIVE PRODUCTS.

•

LOWER PRICE COMPARED TO COMPETITORS BOTH LOCALLY AND INTERNATIONALLY.

WHY THEY INVESTED IN THE FOREIGN MARKET?

SWOT ANALYSIS  STRENGTHS: •

STRONG BRAND IMAGE- IMPROVED BRAND IMAGE DUE TO EXPORTS IN 40 COUNTRIES.

•

WIDE RANGE OF PRODUCTS- GENERIC MEDICINES AS WELL AS SPECIALIZED MEDICINES.

•

COMPETITIVE PRICE IN BOTH DOMESTIC AND INTERNATIONAL MARKETS.

•

LARGE DOMESTIC MARKET WITH REASONABLE GROWTH RATE: CONSUMER SPENDING IS INCREASING IN HEALTH CARE PARALLEL TO POPULATION INCREASE.

 WEAKNESSES: •

ABSENCE OF INTERNATIONAL STANDARD QUALITY CONTROL AND TESTING LABORATORY

•

LITTLE RESEARCH AND DEVELOPMENT ON NEW MOLECULE DEVELOPMENT ETC.

SWOT ANALYSIS (CONTINUED)  OPPORTUNITIES: •

LARGE POTENTIAL FOR EXPORT MARKET EXPANSION

•

SCOPE FOR PRODUCT DIVERSIFICATION

•

SCOPE TO TAKE ADVANTAGE OF PARALLEL IMPORTS.

•

RESEARCH AND DEVELOPMENT ACTIVITIES MAY BE INITIATED WITH EXTERNAL SUPPORT.

 THREATS: •

CHEAPER MEDICINE FROM CHINA AND INDIA.

•

COUNTRIES SUPPLYING PRODUCTS THROUGH UNAUTHORIZED CHANNELS.

•

INCREASE OF PRICE OF RAW MATERIALS.

SUMMARIZING THE SWOT  AVAILING OPPORTUNITIES •

•

•

USING STRENGTH:

USING PARALLEL IMPORTS TO AVAIL THE ADVANTAGE OF LARGE DOMESTIC MARKET. ENTER NEW MARKETS TO AVAIL THE ADVANTAGE OF BEING VIEWED AS A CHEAP BUT QUALITY MEDICINE PROVIDER. DIVERSIFY TO HERBAL MEDICINES AND MEDICINES FOR ANIMALS TO USE THE EXISTING RESOURCES MORE EFFICIENTLY.

 WHY

EXPORTING?

MARKET SEEKING PURPOSE- A BIGGER MARKET WILL ALLOW THE COMPANY TO PRODUCE MORE PRODUCTS, THUS IT WILL LET THE COMPANY TO AVAIL THE ADVANTAGES OF ECONOMIES OF SCALE, THUS COMPETING BETTER WITH CHINA AND INDIA.

WHAT FACTORS DID THEY CONSIDER WHILE INVESTING IN THE FOREIGN MARKET?

EXTERNAL FACTORS

•

PARTNERSHIPS AND TECHNOLOGY TRANSFER IN EXPORT OPERATION.

•

CURRENTLY THE COMPANY IS EXPLORING DISTRIBUTORSHIP, CONTRACT MANUFACTURING, IN LICENSING, TECHNOLOGY PARTNERSHIP AND MANY OTHER FORMS OF COOPERATION IN VARIOUS COUNTRIES AROUND THE WORLD.

INDUSTRIAL FACTORS

EXPORT TO THE WORLD.

•

INCEPTA’S

•

INCEPTA CURRENTLY SELLS ITS PRODUCT IN MANY COUNTRIES OF ASIA, AFRICA, CENTRAL AND LATIN AMERICA AND HAS STARTED TO SELL IN EUROPE.

WHAT PROCESS DID THEY FOLLOW?

WHAT WAS THE SELECTION PRICESS TO GOT TO OTHER MARKETS? •

IT ONLY TAKES THIRTEEN DAYS TO SET UP A COMPANY IN THE UNITED KINGDOM

•

THE FOREIGN COMPANIES ARE ALSO TREATED AS A LOCAL COMPANY ONCE IT HAS BEEN REGISTERED

•

LOW TAXATION MAKES THE ENVIRONMENT INVESTOR-FRIENDLY AND LONDON IS ONE OF THE WORLD'S LEADING FINANCE CAPITALS

•

CURRENTLY INCEPTA EXPORTS TO 60 DIFFERENT COUNTRIES AROUND THE WORLD

THE STAGES OF SELECTION •

SUBSTITUTE PRODUCTS AND ACCESS TO ALL THE RAW MATERIALS.

•

COUNTRY’S GOVERNMENT REGULATIONS AND POLICIES ON INVESTMENT.

•

AVAILABILITY OF APPROPRIATE AND SKILLED HUMAN RESOURCE.

•

ECONOMIC GROWTH OF THE COUNTRY.

•

POLITICAL STABILITY.

•

COST AND EASE OF DOING BUSINESS.

HOW WAS IT POSSIBLE? WAS THERE ANY PROBLEM? ACQUISITION THIS FIRM ACQUIRE, THE FINANCIAL PUBLIC RELATIONS AND MARKETING GROUP, IS IN TALKS OVER AN ALL-SHARE MERGER WITH RIVAL HUNTSWORTH.

PROBLEM INTEGRATING FOREIGN SUBSIDIARIES INTO THE

PARENT’S SYSTEM.

STRATEGY OF THE FIRM

WHAT HAD BEEN THE MAJOR AND OTHER IMPORTANT ISSUES THEY FACED DURING THE INTERNATIONALIZATION PROCESS?

•

KEY MANAGERIAL POSITIONS

•

CULTURAL BARRIERS

•

TAX SYSTEMS

FUTURE PLANS •

INCEPTA

PHARMACEUTICALS

LIMITED,

SWISS

BIOTECH

EQUIPMENT

MANUFACTURER

BIOENGINEERING AND GERMAN AMS TECHNOLOGY HAVE JOINTLY LAUNCHED A COMPANY CALLED ‘SWISS BIOHYGIENIC EQUIPMENT‘AT RADISSON BLU ON 28TH SEPTEMBER, 2016.

•

FROM THE VERY BEGINNING, INCEPTA HAS FOCUSED ON LAUNCHING NEWER AND INNOVATIVE PRODUCTS. HIGH INVESTMENT IN R&D AND ADVANCED TECHNOLOGY HAS ALLOWED THE COMPANY TO LAUNCH 429 GENERICS WITH 783 PRESENTATIONS, 158 OF WHICH WERE INTRODUCED “FIRST TIME IN BANGLADESH”.

ENDING REMARKS FROM OUR PRESENTATION

CONCLUSION •

•

•

•

•

INCEPTA STRONGLY BELIEVES THAT COMMITMENT TOWARDS PEOPLE AND THE SOCIETY AS A WHOLE POSITIVELY CONTRIBUTES TOWARDS ITS BUSINESS OBJECTIVE. INCEPTA ADOPTS DIFFERENT STRATEGIES, WHICH CREATE A SUSTAINABLE ADVANTAGE FOR THE COMPANY. IT IS THE FIRST BANGLADESHI PHARMACEUTICAL COMPANY TO IMPLEMENT SAP TO MANAGE RESOURCES THROUGHOUT THE COMPANY OPERATION. THIS WORLD CLASS RESOURCE MANAGEMENT SYSTEM ALLOWS THE COMPANY TO BECOME MORE EFFICIENT AND EFFECTIVE IN ITS DAY TO DAY OPERATION. INCEPTA IS TAKING SPECIAL EFFORTS TO ENSURE PRESENCE IN THE REST OF THE GLOBE.